Hepatic stellate cells as key target in liver fibrosis

• Published in: Advanced drug delivery reviews Vol. 121; pp. 27 - 42
• Main Authors: Higashi, Takaaki, Friedman, Scott L., Hoshida, Yujin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.2017
• Subjects: Alcoholic liver disease; Cirrhosis; Hepatitis; Myofibroblast; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; CXCL; RAR; TWEAK; ATX; JNK; NF-kB; HMGB1; TNF; DNMT; PRR; Hepatitis; UTR; PPAR; Th; UPR; HSC; iNOS; LRAT; Non-alcoholic steatohepatitis; HBV; Hh; IL; SREBP; FGF; HGF; AT1R; DKK1; ER; ARB; MMP; Cirrhosis; TGF; VAP-1; CCl4; ROS; AMPK; LY6C; HCV; LPA; CVCR; ERK; FXR; MeCP2; NO; NAFLD; LSEC; Myofibroblast; BDL; RXR; CpG; TLR; CB; ACE; EGF; VDR; ASK1; VEGF; NASH; OCA; CCL; ECM; Alcoholic liver disease; PAMP; STAT; 5-HT(2B); CCR; PDGF; Non-alcoholic fatty liver disease; DAMP; EZH2; TZD

Progressive liver fibrosis, induced by chronic viral and metabolic disorders, leads to more than one million deaths annually via development of cirrhosis, although no antifibrotic therapy has been approved to date. Transdifferentiation (or “activation”) of hepatic stellate cells is the major cellula...